(Q33370243)

English

Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Chih-Hung Hsu

2

0 references

Chao-Yuan Huang

object named as

Chao-Yuan Huang

3

0 references

object named as

Yeong-Shiau Pu

7

0 references

object named as

Ann-Lii Cheng

4

0 references

Nicholas J. Vogelzang

6

object named as

Nicholas J Vogelzang

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Chia-Chi Lin

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jun Chen

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

106

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1269-1275

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

21 January 2018

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

21 January 2018

The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

21 January 2018

5-Fluorouracil, interferon-alpha-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study. Hellenic Co-operative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

21 January 2018

Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

21 January 2018

A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

21 January 2018

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

7 January 2021

based on heuristic

inferred from DOI database lookup

Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

7 January 2021

based on heuristic

inferred from DOI database lookup

Median follow-up in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal toxicity to myeloid progenitor cells of weekly 24-hr infusion of high-dose 5-fluorouracil: direct evidence from colony forming unit-granulocyte and monocyte (CFU-GM) clonogenic assay

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of cisplatin, 5-fluorouracil, and interferon-alpha-2B as first line treatment of advanced urothelial cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21738

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21738

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33370243&oldid=2201352642"